Re Agreement

RNS Number:8580M
Advanced Medical Solutions Grp PLC
27 June 2003


                                                                  27th June 2003


         Advanced Medical Solutions Group plc ("AMS" or the "Company")

                Announces Supply Agreement with Johnson & Johnson

                 Wound Management - a Division of ETHICON, Inc.


      For Silver Alginate Dressings for the Professional Wound Care Market

Winsford, UK: AMS, the global woundcare technology company has today announced
an exclusive supply agreement with Johnson & Johnson Wound Management for a
range of alginate woundcare dressings containing silver.

In May 2002, AMS announced a collaboration with Johnson & Johnson Wound
Management to supply a range of calcium alginate products for launch under their
NuDerm* brand.

In January 2002, AMS announced that it had agreed an option to license X-STATIC(R)
silver fibre technology from Noble Fiber Technologies Inc ("Noble"). This
agreement enabled AMS to use X-STATIC(R) silver fibres in its alginate based
woundcare dressings and granted AMS exclusive world-wide rights to seek
marketing partners for these products. This option has now been exercised and an
exclusive agreement has been reached between AMS and Noble for the supply of
Noble's X-STATIC(R) silver fibres for use in calcium alginate woundcare dressings
for supply to Johnson & Johnson Wound Management for sale into the Professional
Woundcare market.

Silver is widely recognised as a safe and effective broad-spectrum
anti-microbial agent for infection control. The X-STATIC(R) silver fibre
technology utilises a layer of pure silver, bonded to the surface of a textile
fibre, which enables it to be incorporated into an alginate dressing.

AMS has subsequently developed calcium alginate products, which allow a
controlled and sustained release of silver into the wound without compromising
the performance of the alginate as a wound dressing.

Under the terms of the agreement announced today, Johnson & Johnson Wound
Management will act as AMS' global exclusive marketing partner for these
products, which will be marketed by Johnson & Johnson Wound Management under its
SilverCelTM brand. It is expected that these products will be launched into the
Professional Woundcare market during Qtr.3 2003 following 510(k) and CE Mark
regulatory approvals, which are currently underway.

Commenting on this agreement, Dr Don Evans, Chief Executive Officer of AMS,
said:

"We are delighted to have extended our relationship with Johnson & Johnson Wound
Management. This agreement, which underlines our strategy of partnering with
leading international companies to bring higher value products into the advanced
woundcare market, is an excellent endorsement of our alginate technology."


          ___________________________________________________________

In a separate statement about trading conditions Don Evans commented:

"Against the challenging economic background of the last few months, coupled
with the disruptive effect of the AVRC resolution defeated at our AGM, we are
pleased that the recent series of announcements represent a continuation of our
progress in exploiting our technology."

                                    - ENDS -


For further information, please contact:

Advanced Medical Solutions Group plc     Tel : [phone]
Don Evans, Chief Executive Officer
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                 Tel: [phone]
Nicola How
Fergus Mellon                           Mobile [phone]


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the #15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to A & E
departments or through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
AGRNKAKBBBKBOAB